Scientists that discovered a life-saving drug to treat cancer patients with a faulty gene are marking a special anniversary, and looking back at the impact their work has had around the world.

Recent FDA approvals have included Rubraca (rucaparib), which was approved in 2020 for patients with metastatic castration-resistant prostate cancer that expresses a BRCA mutation, and Lynparza ...

However, the approaches within these trials resemble the Olaparib trials. Rucaparib and Niraparib are being investigated in platinum sensitive ovarian cancers as a maintenance therapy (NCT01968213 ...

Medically reviewed by Marla Anderson, MDCancer is as old as humanity, and the history of breast cancer is a fantastic example ...

November 12, 2024 • A federal judge sentenced Jack Teixeira, a Massachusetts Air National Guard member, to prison after he pleaded guilty to leaking highly classified military documents about ...

At Mar-a-Lago, ‘Uncle’ Elon Musk Puts His Imprint on the Trump Transition He’s on the patio. He’s on the golf course. Everywhere President-elect Trump looks, there is the world’s richest ...

Nov. 11, 2024 — Why is the expansion of our Universe accelerating? Twenty-five years after its discovery, this phenomenon remains one of the greatest scientific mysteries. Solving it involves ...

Nov. 13, 2024 — Few questions have captivated humankind more than the origin of life on Earth. How did the first living cells come to exist? How did these early protocells develop the structural ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

Justin Welby, the leader of 85 million Anglicans worldwide, announced his resignation days after a report found he had taken insufficient action over claims of abuse. By Stephen Castle and Mark ...

A trader works at the New York Stock Exchange (NYSE), after Republican presidential nominee Donald Trump won the election, in New York City, U.S., November 6, 2024. REUTERS/Andrew Kelly/File Photo ...

Japanese gynecological benign tumor market is thriving with cutting-edge diagnostic technologies and minimally invasive ...